Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro

Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies

(2015) Ann L. White et al.   CANCER CELL

Engineering disulfide bonds within an antibody

(2014) Yoshihisa Hagihara et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

The Fab Conformations in the Solution Structure of Human Immunoglobulin G4 (IgG4) Restrict Access to Its Fc Region

(2014) Lucy E. Rayner et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Accelerated therapeutic progress in diffuse large B cell lymphoma

(2013) Qingqing Cai et al.   ANNALS OF HEMATOLOGY

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

(2013) Christian Klein et al.   mAbs

Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions

(2013) Christian Kellner et al.   METHODS

Isotype and glycoform selection for antibody therapeutics

(2012) Roy Jefferis   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway

(2012) J. Honeychurch et al.   BLOOD

Disulfide bond structures of IgG molecules

(2012) Hongcheng Liu et al.   mAbs

Molecular engineering to improve antibodies’ anti-lymphoma activity

(2011) Matthias Peipp et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

CD20 antibodies: doing the time warp

(2011) M. S. Cragg   BLOOD

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

(2011) W. Alduaij et al.   BLOOD

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

(2011) G. Niederfellner et al.   BLOOD

Optimizing Therapeutic Antibody Function

(2010) Etsuji Kaneko et al.   BIODRUGS

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

(2010) Gregory L. Moore et al.   mAbs

Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding

(2010) Sandra Lightle et al.   PROTEIN SCIENCE

CD20-Targeted Therapy: The Next Generation of Antibodies

(2010) Tom van Meerten et al.   SEMINARS IN HEMATOLOGY

Rituximab: Mechanism of Action

(2010) George J. Weiner   SEMINARS IN HEMATOLOGY

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood

(2009) Shigeru Iida et al.   BMC CANCER

Engineered therapeutic antibodies with improved effector functions

(2009) Tsuguo Kubota et al.   CANCER SCIENCE